EDGAR·FLOW

Jasper Therapeutics, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 28/100
What the filing says
Mirador Therapeutics licenses exclusive worldwide rights to develop and commercialize Kira's C5a-targeting monoclonal antibody (KP301) and C5aR-targeting small molecule (KP402) from Kira Pharmaceuticals under a July 2026 agreement. Mirador pays $12M upfront, $8M upon physical materials delivery, up to $284M in development/commercial milestones, and tiered royalties on net sales capped at an effective rate. Kira retains obligations to University of Pennsylvania under its June 2017 license agreement.
Why this rating

Routine sublicense by early-stage biotech. At $74.8M market cap, $12M upfront is 16% of company value—meaningful but standard for asset-out licensing. Mirador assumes full development risk; Kira receives cash flow but loses control. Limited near-term revenue impact; long-term value depends on Mirador's success with compounds at pre-clinical/early clinical stage.

View original filing on SEC.gov ↗ JSPR · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.